» Articles » PMID: 9684740

New Lysosomal Acid Lipase Gene Mutants Explain the Phenotype of Wolman Disease and Cholesteryl Ester Storage Disease

Overview
Journal J Lipid Res
Publisher Elsevier
Specialty Biochemistry
Date 1998 Jul 31
PMID 9684740
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Deficiency of lysosomal acid lipase (LAL) leads to either Wolman disease (WD) or the more benign cholesteryl ester storage disease (CESD). To identify the molecular basis of the different phenotypes we have characterised the LAL gene mutations in three new patients with LAL deficiency. A patient with WD was homozygote for a null allele Y303X. The other two patients, with CESD, presented either homozygosity for T267I or compound heterozygosity consisting of Q64R and an exon 8 donor splice site substitution (G-->A in position -1). The mutants T267I and Q64R and the previously reported L273S, G66V, and H274Y CESD substitutions, overexpressed in stable clones, were found to be fully glycosylated and show an enzymatic activity of 3-8% of that of normal LAL. On the other hand, the delta254-277 mutant protein derived from exon 8 skipping and the Y303X protein were totally inactive. By transient transfection of hybrid minigene constructs, the CESD G-->A (-1) substitution resulted in partial exon inclusion, thus allowing the production of a small amount of normal LAL mRNA and hence of a functional enzyme. In contrast, a G-->A substitution observed in WD at position + 1 of the same exon 8 donor site resulted in complete exon skipping and the sole production of an inactive delta254-277 protein. In conclusion, LAL genotypes determine the level of residual enzymatic activity, thus explaining the severity of the phenotype.

Citing Articles

Pedigree Analysis of Nonclassical Cholesteryl Ester Storage Disease with Dominant Inheritance in a LIPA I378T Heterozygous Carrier.

Zhang J, Lin A, Zhang L, Ruan D, Gao M, Chen Q Dig Dis Sci. 2024; 69(6):2109-2122.

PMID: 38564148 DOI: 10.1007/s10620-024-08395-9.


Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023.

Katsiki N, Filippatos T, Vlachopoulos C, Panagiotakos D, Milionis H, Tselepis A Atheroscler Plus. 2024; 55:74-92.

PMID: 38425675 PMC: 10901915. DOI: 10.1016/j.athplu.2024.01.004.


First LIPA Mutational Analysis in Egyptian Patients Reveals One Novel Variant: Wolman Disease.

Elaraby N, Galal E, Abdel-Hamid M, Elbendary H, Elbadry M, Mekkawy M J Mol Neurosci. 2023; 73(7-8):598-607.

PMID: 37470904 PMC: 10517033. DOI: 10.1007/s12031-023-02139-6.


Lysosomal acid lipase deficiency: A rare inherited dyslipidemia but potential ubiquitous factor in the development of atherosclerosis and fatty liver disease.

Besler K, Blanchard V, Francis G Front Genet. 2022; 13:1013266.

PMID: 36204319 PMC: 9530988. DOI: 10.3389/fgene.2022.1013266.


Off-target effects of the lysosomal acid lipase inhibitors Lalistat-1 and Lalistat-2 on neutral lipid hydrolases.

Bradic I, Kuentzel K, Honeder S, Grabner G, Vujic N, Zimmermann R Mol Metab. 2022; 61:101510.

PMID: 35504532 PMC: 9118473. DOI: 10.1016/j.molmet.2022.101510.